Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides by Morisseau, Christophe et al.
Louisiana State University 
LSU Digital Commons 
Faculty Publications Department of Biological Sciences 
7-1-2013 
Inhibition of soluble epoxide hydrolase by fulvestrant and 
sulfoxides 
Christophe Morisseau 
UC Davis Comprehensive Cancer Center 
Svitlana Pakhomova 
Louisiana State University 
Sung Hee Hwang 
UC Davis Comprehensive Cancer Center 
Marcia E. Newcomer 
Louisiana State University 
Bruce D. Hammock 
UC Davis Comprehensive Cancer Center 
Follow this and additional works at: https://digitalcommons.lsu.edu/biosci_pubs 
Recommended Citation 
Morisseau, C., Pakhomova, S., Hwang, S., Newcomer, M., & Hammock, B. (2013). Inhibition of soluble 
epoxide hydrolase by fulvestrant and sulfoxides. Bioorganic and Medicinal Chemistry Letters, 23 (13), 
3818-3821. https://doi.org/10.1016/j.bmcl.2013.04.083 
This Article is brought to you for free and open access by the Department of Biological Sciences at LSU Digital 
Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital 
Commons. For more information, please contact ir@lsu.edu. 
Inhibition of soluble epoxide hydrolase by fulvestrant and
sulfoxides
Christophe Morisseaua,*, Svitlana Pakhomovab, Sung Hee Hwanga, Marcia E Newcomerb,
and Bruce D. Hammocka
aDepartment of Entomology and UCD Comprehensive Cancer Center, One Shields Avenue,
University of California, Davis C.A. 95616, U.S.A
bDepartment of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803
Abstract
The soluble epoxide hydrolase (sEH) is a key enzyme in the metabolism of epoxy-fatty acids,
signaling molecules involved in numerous biologies. Toward finding novel inhibitors of sEH, a
library of known drugs was tested for inhibition of sEH. We found that fulvestrant, an anticancer
agent, is a potent (KI = 26 nM) competitive inhibitor of sEH. From this observation we found that
alkyl-sulfoxides represent a new kind of pharmacophore for the inhibition of sEH.
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In mammals, epoxides of arachidonic acids (called epoxy-eicosatrienoic acids or EETs) and
of other fatty acids are important lipid mediators that have key roles in the regulation of
hypertension, inflammation, and other cardiovascular related diseases as well as in
modulating both inflammatory and neuropathic pain.1 However, endogenous metabolism of
these epoxy-fatty acids to their corresponding hydrated products by soluble epoxide
hydrolase (sEH EC 3.3.2.10) generally reduces these biological activities.2–4 Both in vitro
and in vivo studies have demonstrated that the anti-hypertensive and cardio protective
effects mediated by the EETs are inversely dependent on the extent of sEH hydrolysis of the
EETs.2–4 Thus, maintaining the in vivo concentration of EETs through sEH inhibition is a
promising therapeutic pathway to treat cardiovascular and other diseases.2–4
Based on the catalytic mechanism and structure of sEH,3,5 1,3-disubstituted ureas, amides
and carbamate were found to be potent and stable competitive inhibitors of sEH.6 Over the
years, more potent urea-inhibitors that display better solubility and availability as well as
significant biological activities in both in vitro and in vivo models were obtained.7
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Interestingly, beside the effort of many groups and the screening of several libraries of small
chemicals,8–12 to date only the Merck group was successful in replacing the urea or amide
pharmacophore with a benzisoxazole, which inhibit the sEH in the nanomolar range.10
Recently, chalcone13 and benzoxazolone14 derivatives as well as salvionic acid A15 were
reported to inhibit sEH; however, these compounds are at least a 1,000-fold less potent than
the best sEH inhibitors available.7 These results underline the difficulty to discover novel
pharmacophores that could potently inhibit the human sEH.
The urea function is not used often as pharmacophore for drugs, while amides are used more
frequently. Interestingly, an anti-cancer agent (sorafenib), and an anti-bacterial agent
(triclocarban) that are both containing ureas as central pharmacophore, have, beside their
targeted action, potent sEH inhibitory activity leading to a reduction in pain and
inflammation.16,17 In addition, we observed that co-inhibition of sEH with cyclooxygenase
(COX), lipoxygenase or phosphodiesterase (PDE) has beneficial effects.4 The co-inhibition
of sEH and COX-2 strongly reduces inflammation and pain, but also reduces dose and side
effects of COX-2 inhibitors.18–20 Co-administration of PDE4 inhibitors enhances the action
of sEH inhibitors and EETs in reducing allodynia and hyperalgesia of the enhanced pain
state.21 In general, sEH inhibition appears to enhance the action and improve the safety
profile of current pharmaceuticals.4 Thus, it is attractive to test the concept that active
pharmaceutical ingredients with sEH inhibition will be more active and safer.
Toward testing this hypothesis, we, thus, report herein the screening of a non-targeted
commercial chemical library of drugs: the Pharmakon 1600 (MicroSource Discovery
Systems, Gaylordsville, CT) for sEH inhibition. This library is a unique collection of 1,600
known drugs (20 plates of 80 compounds at 10 mM in DMSO) from US and International
Pharmacopeia, which have all reached clinical evaluation and not simply demonstrated
biological activity experimentally. Most of the constituent drugs are still in the market.
Using recombinant purified human sEH and the fluorescent substrate PHOME ((3-phenyl-
oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester), we screened the
library at a final concentration of 10 μM, following a previously described methodology.22
Overall, we obtained on average for the 20 plates S/B = 7.5 ± 0.4, S/N = 107 ± 25 and Z' =
0.90 ± 0.03 indicating that the assay performed very well. As shown on Fig. 1A, most
compounds did not yield any significant inhibition (< 20%) of the human sEH, and only ten
compounds gave a strong inhibition (> 80% inhibition). To confirm the potency of these
compounds, fresh solutions in DMSO were prepared, and their inhibitory potency (IC50s)
were determined using CMNPC (cyano(6-methoxy-naphthelen-2-yl)methyl trans-[(3-
phenyl-oxiran-2-yl)methyl] carbonate)as substrate.23 As shown on Fig. 1B, only two
compounds gave potent inhibition: fulvestrant (#15G10, IC50 = 6 ± 1 nM), and ebselen
(#18H06, IC50 = 2,200 ± 300 nM). We recently reported that ebselen irreversibly inhibit
sEH through binding to its N-terminal domain.24,25 For the other positive hit (fulvestrant), to
our knowledge, this is the first report of inhibition of sEH by a compound that contains a
sulfoxide as central pharmacophore. The observed potency of fulvestrant is of the same
order as potent urea/amide containing inhibitors developed over the past decade.7
To test the selectivity of fulvestrant toward sEH, we tested its ability to inhibit a series of
related enzymes: sEH-phosphatase activity as well as human microsomal EH, human
alkaline phosphatase and a series of esterases and amidases.26 Fulvestrant was found to only
inhibit the sEH. We then tested if fulvestrant inhibition was reversible. After incubating 20
nM of human sEH with 10 μM of fulvestrant for 15 min, the enzyme was dialyzed to
remove the small molecule. Following this procedure, we were able to recover more than
80% of the sEH activity, suggesting that fulvestrant inhibition of the sEH is reversible. To
define the potency of fulvestrant as a sEH inhibitor, we determined its dissociation constant
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(KI; see Fig. 2) using a radioactivity-based assay.16 The fact that the KIapp values increase
with the concentration of substrate (Fig. 2 insert) strongly suggests that fulvestrant is a
competitive inhibitor of the sEH like the urea/amide inhibitors.3,6,7 Fulvestrant has a KI of
26 nM, which is approximately 10-fold higher than that of the very potent t-AUCB (KI = 1.5
nM), the compound used as positive control for the screening, but similar to the KI of other
potent sEH inhibitors (7 < KI < 57 nM),16 especially of the one (TPAU) used in phase I and
II clinical trials.27
To confirm the binding site and mode of action of fulvestrant, we obtained crystals of the
human sEH complexed with fulvestrant (see supplementary data for method and crystal
details). The X-ray structure of the crystal (Fig. 3) showed that fulvestrant binds in the
hydrolase catalytic pocket of sEH. Furthermore, the oxygen atom of the sulfoxide
pharmacophore makes hydrogen bonds with two key catalytic residues: tyrosines 383 and
466 (Fig. 3), in a manner very similar to the way the carbonyl of urea inhibitors bind at the
active site of sEH.3,5,7 Interestingly, interaction between the sulfur atom of fulvestrant and
Asp335 is observed that is similar to the bond observed between the Nh groups of the urea
and the catalytic Asp335 residue.3,5,7 Sulfoxides are highly polar groups with a strong
positive charge on the sulfur atom,28 thus enhancing the feasibility of a strong bond between
the sulfur atom and the enzyme catalytic Asp335. These observations confirm that fulvestrant
is a competitive inhibitor of sEH. Close examination of the structure revealed that the
fluorinated alkyl chain of fulvestrant occupies the smaller of the two lipophilic pockets in
the sEH active site, while the steroid part of the molecule is directed towards the large deep
pocket that opens toward solvent. Interestingly, while too far for establishing a hydrogen
bond (5.37 Å) the hydroxyl group on the aromatic ring is pointing toward the amide nitrogen
of Asn472. On the other end, the cyclopentyl ring of fulvestrant is at the entrance of the
catalytic tunnel with the hydroxyl group on this ring facing outward toward the solvent. The
rings are enveloped by numerous hydrophobic residues underlying the strong
hydrophobicity of the pocket. Finally, the observation that the ring structure of fulvestrant
can fit inside the catalytic cavity of sEH is quite unexpected and suggest that sEH can bind
and probably hydrolyze, substrates that are larger than the ones for which it is reported to be
active on.29
To test if the observed inhibition of sEH is specific to the sulfoxide group of fulvestrant, we
measured the potency of several sulfoxides (Table 1). Of the three sulfoxides tested (1–3),
two of them (2 and 3) gave significant inhibition of sEH, confirming that sulfoxides in
general could inhibit sEH. Interestingly, replacement of aryl groups by alkyl groups in
compounds 1 to 3 yields more potent inhibitors. The difference in potency between
compounds 1 and 3 is probably due to steric effects by rigid benzyl group, because the
catalytic tunnel is relatively constricted around the catalytic residues.3,5 The most potent
compound tested 3 is around 100-fold less potent than fulvestrant, suggesting that the
hydrophobic interactions from the steroid rings and the pentafluoropentane play a significant
part in the binding of fulvestrant. Compared to 1, the corresponding amide 4 and urea 5 are
significantly more potent, suggesting that the amide and urea form a stronger network of
interactions with the enzyme than the sulfoxide. This is probably due to the absence of
hydrogen bonds to stabilize the dipole-dipole interaction of the sulfur atom with the catalytic
carboxylic acid, as such bonds do for the urea/amide pharmacophore.3 Replacement of the
sulfur atom of 3 by a carbon, to yield the ketone 6, resulted in a total loss of potency. This
underlines the necessity of a strong dipole moment on the central pharmacophore to
establish strong hydrogen bonds with the enzyme residues. Finally, we tested if the degree
of oxidation of the sulfur atom influences the potency of the compound. Both the thio-ether
7 and the sulfone 8 displayed a greater loss of potency (> 100-fold) compared to sulfoxide 3.
Sulfones are more polar than corresponding sulfoxides,28 thus, the charge on the sulfur atom
of 8 should be greater than the charge on the sulfur atom of 3 leading to greater inhibition.
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The fact that 8 is less potent than 3 suggests that some steric constrains probably impede the
sulfone from binding efficiently into the active site of sEH.
Taken together, the results obtained clearly show that sulfoxides represent a new class of
competitive sEH inhibitors, with alkyl sulfoxides being the most potent. In this class of
compound, fulvestrant was found to have a low nanomolar KI for the human sEH.
Fulvestrant is an estrogen receptor antagonist used for the treatment of hormone receptor
positive metatastic breast cancer.30 It is beyond the scope of this paper to determine if sEH
inhibition account for part of fulvestrant efficacy. A human pharmaco-kinetic study showed
a blood concentration around 10 nM for several weeks following intramuscular
treatment.31,32 At such a concentration (slightly below the KI), it is unlikely that all the sEH
is inhibited; however a significant portion of it should be. Because sulfones are not
inhibitors of sEH, development of sulfoxides as sEH inhibitors will be limited by their
stability and sensitivity to oxidation. Interestingly, fulvestrant is very stable in humans.31
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A Primary screening results of the Pharmacon library. Percent of sEH inhibition for each
compound tested at 10 μM. Compounds that gave more than 80% inhibition (dashed line)
were selected for secondary screening. B. Secondary screening results. IC50s were measured
using CMNPC as substrate.23 Results are mean ± standard deviation of at least three
separate measurements.
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Determination of the KI of fulvestrant with the human sEH (1 nM) Using [3H]-tDPPO as
substrate. For each substrate concentration (3.6 to 30.0 μM), the velocity is plotted as a
function of sEH inhibitor concentration (0 to 75 nM), allowing the determination of an
apparent inhibition constant (KIapp). KIapps are plotted as a function of the substrate
concentration (insert). For [S] = 0, a KI value of 26 nM was found.
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The active site of the hydrolase domain of human sEH complexed with fulvestrant. The Fo-
Fc electron density map is contoured at 2.5σ. Non-bonded interactions are indicated by
dashes. Coordinates of the complex deposited as 4J03 with the Protein Data Bank. The
image was produced using PYMOL.
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Table 1




2 6,800 ± 300
3 1,350 ± 40
4 11,000 ± 1,000





The IC50s were measured using CMNPC as substrate.23 Results are mean ± standard deviation of at least three separate measurements.
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